Business Wire

CA-FORESCOUT

24.5.2022 14:02:05 CEST | Business Wire | Press release

Share
Forescout Launches Forescout Frontline to Help Organizations Tackle Ransomware and Real Time Threats

Forescout Technologies , the leader in automated cybersecurity, today announced the launch of Forescout Frontline , a new threat hunting service utilizing a team of highly-trained cybersecurity analysts to support cybersecurity teams by proactively identifying risks, enabling accelerated incident response, and maturing security posture. Forescout is offering this complimentary service for organizations that lack the internal resources and visibility to defend themselves from cybersecurity attacks, including ransomware and advanced persistent threats (APT).

“Cybersecurity attacks are on the rise. Simultaneously, cybersecurity teams are perennially understaffed and under resourced. This has created a perfect storm,” said Shawn Taylor, vice president of threat defense. “Organizations are under immense pressure to cope with the scale and speed of attacks and the havoc caused by the adversaries. Forescout is launching this new service to help organizations defend against attacks by providing a complete and holistic view of their assets.”

Many organizations use multiple security tools across multiple teams to help identify threats and risks. However, insights may be limited due to siloed views of IT, IoT, IoMT or OT assets. Typically, a variety of these asset types exist across an organization’s digital terrain and are often interconnected, which means cybersecurity risk must be identified and tackled holistically.

Delivered by Forescout Frontline analysts, the Threat Hunting and Risk Identification Service overcomes staffing resources and asset visibility challenges to uncover threats and identify risks that may otherwise remain undiscovered. Forescout Frontline will help organizations:

  • Discover, validate and prioritize a wide variety of cyber threats and vulnerabilities across all assets, including IT, IoT, IoMT and OT
  • Analyze the context and risk associated with all findings
  • Leverage the comprehensive insights to develop effective risk mitigation and remediation strategies

A State of Florida Agency, which supports several key Florida departments, engaged Forescout Frontline to understand each instance of Log4j, a zero-day vulnerability in a popular Java logging framework, across the organization’s 220 sites in 16 diverse divisions. In less than a day and a half, Forescout Frontline delivered insights into thousands of assets with vulnerabilities such as Log4j and Windows-based PrintNightmare. Additionally, hundreds of Critical CVSS-rated vulnerabilities affecting infrastructure devices such as switches and routers were found. Finally, actionable intelligence concerning critical embedded IoT TCP-IP stack-based instances such as NUCLEUS: 13 and RIPPLE 20, insecure communications, and other risks were also discovered. Leveraging this free service shrunk time to mitigation and remediation of these security gaps and improved overall security posture.

“When Log4J broke, we knew it was a critical issue, but we lacked a full picture of the risk within our extended enterprise. The [Forescout threat hunting] report was way more thorough than I expected, with in-depth information and actionable intelligence. Not just on Log4j but on other critical vulnerabilities as well, and not just in general terms but exactly where they exist in our environment.” – Information Security Manager, State of Florida Agency

Forescout Frontline levels the cybersecurity playing field by operationalizing the vulnerability research and threat intelligence produced by Forescout’s Vedere Labs and enhancing it with the Forescout Continuum Platform to provide threat hunting services across multiple dimensions. Forescout Frontline analysts include former public sector and private sector threat hunters with training in threat detection and incident response.

To learn more about Forescout Frontline, visit here , and for further insight into how a State of Florida agency benefitted from this new service, visit here.

About Forescout

Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types – IT, OT, IoT, IoMT. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets.

Managing cyber risk, together.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye